The estimated Net Worth of Neil Bodick is at least $3.97 Million dollars as of 3 January 2020. Dr Bodick owns over 3,851 units of Flexion Therapeutics Inc stock worth over $920,406 and over the last 11 years he sold FLXN stock worth over $2,389,169. In addition, he makes $657,598 as Consultant at Flexion Therapeutics Inc.
Sign up
Dr Bodick FLXN stock SEC Form 4 insiders trading
Dr has made over 24 trades of the Flexion Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 3,851 units of FLXN stock worth $35,391 on 3 January 2020.
The largest trade he's ever made was selling 50,000 units of Flexion Therapeutics Inc stock on 2 July 2018 worth over $1,253,500. On average, Dr trades about 4,921 units every 54 days since 2014. As of 3 January 2020 he still owns at least 100,153 units of Flexion Therapeutics Inc stock.
You can see the complete history of Dr Bodick stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Neil Bodick biography
Dr. Neil Bodick is the Consultant at Flexion Therapeutics Inc.
What is the salary of Dr Bodick?
As the Consultant of Flexion Therapeutics Inc, the total compensation of Dr Bodick at Flexion Therapeutics Inc is $657,598. There are 4 executives at Flexion Therapeutics Inc getting paid more, with Michael Clayman having the highest compensation of $3,777,360.
How old is Dr Bodick?
Dr Bodick is 73, he's been the Consultant of Flexion Therapeutics Inc since . There are 1 older and 15 younger executives at Flexion Therapeutics Inc. The oldest executive at Flexion Therapeutics Inc is Samuel Colella, 80, who is the Independent Director.
What's Dr Bodick's mailing address?
Neil's mailing address filed with the SEC is C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON, MA, 01803.
Insiders trading at Flexion Therapeutics Inc
Over the last 11 years, insiders at Flexion Therapeutics Inc have traded over $7,066,621 worth of Flexion Therapeutics Inc stock and bought 7,091,809 units worth $98,920,816 . The most active insiders traders include Holdings A/S Novo, Bradley J Ph D Bolzon, and Samuel D Colella. On average, Flexion Therapeutics Inc executives and independent directors trade stock every 24 days with the average trade being worth of $609,564. The most recent stock trade was executed by Christina Willwerth on 19 July 2021, trading 3,945 units of FLXN stock currently worth $25,445.
What does Flexion Therapeutics Inc do?
Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company's core values are focus, ingenuity, tenacity, transparency and fun.
What does Flexion Therapeutics Inc's logo look like?
Complete history of Dr Bodick stock trades at Flexion Therapeutics Inc
Flexion Therapeutics Inc executives and stock owners
Flexion Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Michael Clayman,
President, Chief Executive Officer, Director -
David Arkowitz,
Chief Financial Officer -
Scott Kelley,
Chief Medical Officer -
Mark Levine,
General Counsel and Corporate Secretary -
Dr. Neil Bodick,
Consultant -
Patrick Mahaffy,
Independent Chairman of the Board -
Sandesh Mahatme,
Independent Director -
Samuel Colella,
Independent Director -
Alan Milinazzo,
Independent Director -
Mark Stejbach,
Independent Director -
C. Ann Merrifield,
Independent Director -
Scott Canute,
Independent Director -
Heath Lukatch,
Independent Director -
Scott Young,
IR Contact Officer -
Elizabeth Kwo,
Director -
Christina Willwerth,
Chief Strategy Officer -
Kerry Wentworth,
Chief Regulatory Officer -
Melissa Layman,
Chief Commercial Officer -
John Magee,
VP of Sales -
Carolyn Beaty Scimemi,
VP, Legal Affairs & Chief Compliance Officer -
David A. Arkowitz M.B.A.,
Chief Financial Officer -
Ventures Iii, Llc Versant V...,
-
Yamo Deniz,
Chief Medical Officer -
Frederick W Driscoll,
Chief Financial Officer -
Barbara N Bolzon Bradley J ...,
-
William T. Andrews,
Chief Medical Officer -
Utpal Koppikar,
Director -
Neil Bodick,
Chief Scientific Officer -
Ventures Ii Lp5 Am Co Inves...,
-
Holdings A/S Novo,
10% owner -
Partners Sas Sofinnova,
10% owner -
Venture Capital Iii, L.P.Bo...,
-
Venture Capital Iii, L.P.Ve...,
-
Rafael Tordjman,
Director -
Andrew J. Schwab,
Director -
Bradley J Ph D Bolzon,
Director -
Venture Capital Iii, L.P.Ve...,
-
Inc Pfizer,
10% owner -
Management, Llc Newtyn,
10% owner -
Adam Muzikant,
Chief Business Officer